MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells

Despite marked advances in breast cancer therapy, basal-like breast cancer (BBC), an aggressive subtype of breast cancer usually lacking estrogen and progesterone receptors, remains difficult to treat. In this study, we report the identification of MELK as a novel oncogenic kinase from an in vivo tu...

Full description

Bibliographic Details
Main Authors: Yubao Wang, Young-Mi Lee, Lukas Baitsch, Alan Huang, Yi Xiang, Haoxuan Tong, Ana Lako, Thanh Von, Christine Choi, Elgene Lim, Junxia Min, Li Li, Frank Stegmeier, Robert Schlegel, Michael J Eck, Nathanael S Gray, Timothy J Mitchison, Jean J Zhao
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2014-05-01
Series:eLife
Subjects:
Online Access:https://elifesciences.org/articles/01763
Description
Summary:Despite marked advances in breast cancer therapy, basal-like breast cancer (BBC), an aggressive subtype of breast cancer usually lacking estrogen and progesterone receptors, remains difficult to treat. In this study, we report the identification of MELK as a novel oncogenic kinase from an in vivo tumorigenesis screen using a kinome-wide open reading frames (ORFs) library. Analysis of clinical data reveals a high level of MELK overexpression in BBC, a feature that is largely dependent on FoxM1, a master mitotic transcription factor that is also found to be highly overexpressed in BBC. Ablation of MELK selectively impairs proliferation of basal-like, but not luminal breast cancer cells both in vitro and in vivo. Mechanistically, depletion of MELK in BBC cells induces caspase-dependent cell death, preceded by defective mitosis. Finally, we find that Melk is not required for mouse development and physiology. Together, these data indicate that MELK is a normally non-essential kinase, but is critical for BBC and thus represents a promising selective therapeutic target for the most aggressive subtype of breast cancer.
ISSN:2050-084X